Global Adalimumab Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2020
  • Global
  • 350 Pages
  • No of Tables: 496
  • No of Figures: 84

Global Adalimumab Market, By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Adalimumab Market Market Analysis and Insights : Global Adalimumab Market

The adalimumab market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.8% in the forecast period of 2020 to 2027 and is expected to reach USD 28,508.07 million by 2027. Rise in the prevalence of rheumatoid arthritis and increasing number of contract research organizations are the major drivers which propelled the demand of the market in the forecast period.

Adalimumab is one of the monoclonal antibodies and is used for the treatment of certain autoimmune diseases involving rheumatoid arthritis and crohn's diseases among others. Adalimumab is an anti- TNF drug indicated for the treatment of inflammatory symptoms. The biologic of adalimumab is humira and various biosimilar drugs of humira are also available which involves exemptia, hyrimoz, cyltezo and hulio among several others. Adalimumab works by binding to the TNF factor-alpha which reduces the chances of the inflammatory response to autoimmune diseases.

Adalimumab comprises features such as increasing need for better therapeutics options which will impact in launching new product by the manufacturers into the market which enhance its demand as well as increasing investment in research and development leads to the adalimumab market growth. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative adalimumab which is expected to provide various other opportunities in the adalimumab market. However, high cost of drugs and side effects of drugs are expected to restraint the adalimumab market growth in the forecast period.

The adalimumab market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the adalimumab market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Adalimumab Market Global Adalimumab Market Scope and Market Size

The adalimumab market is segmented on the basis of indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of indication, the adalimumab market the market is segmented into rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate and others. In 2020, rheumatoid arthritis segment is dominating the adalimumab market because it is one of the most common autoimmune systemic inflammatory diseases affecting approximately 1% of the worldwide population. Moreover, worldwide, the annual incidence of rheumatoid arthritis is approximately 3 cases per 10,000 populations.
  • On the basis of type, the adalimumab market is segmented into biologics and biosimilars. In 2020, biologics segment is dominating the adalimumab market because less number of biosimilars drugs present worldwide. Moreover, AbbVie have still patent right on the Humira in the U.S. market.
  • On the basis of dosage strength, the adalimumab market is segmented into 40mg/0.4ml, 80mg/0.8ml, 20mg/0.2ml, 10mg/0.1ml and others. In 2020, 40mg/0.4ml is dominating the adalimumab market because majority of population or patients are suffering from inflammatory disease and are relying on 40mg dose in order to achieve effective treatment.
  • On the basis of drug type, the adalimumab market is segmented into branded and generics. In 2020, branded segment is dominating the adalimumab market because patients are more satisfied with the branded product; moreover AbbVie has marketing right for branded Humira all over the world.
  • On the basis of route of administration, the adalimumab market is segmented into parenteral and oral. In 2020, parenteral segment is dominating the adalimumab market because adalimumab is a human monoclonal antibody can only be given through SC route so as to induce slow and effective long term effect.
  • On the basis of population type, the adalimumab market is segmented into adults and children. In 2020, adults segment is dominating the adalimumab market because adult population have weak immune system and thus are more prone to inflammatory diseases and majority of clinical data supporting adalimumab effectiveness among the adult population.
  • On the basis of end user, the adalimumab market the market is segmented into hospitals, specialty clinics, home healthcare and others. In 2020, hospitals segment is dominating the adalimumab market because of the presence of skilled professionals, moreover hospital provides with the insurance coverage for adalimumab drugs.
  • On the basis of distribution channel, the adalimumab market the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, direct tenders and others. In 2020, hospital pharmacies segment is dominating the adalimumab market because of the presence of experienced professional and adalimumab is only prescribed by the doctors, so one can only buy it from the hospital pharmacies at a reasonable price.

Adalimumab Market Adalimumab Market Country Level Analysis

The adalimumab market is analyzed and market size information is provided by country, indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel as referenced above.

The countries covered in the adalimumab market report are the U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Belgium, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.

Biologics segment in North America region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because there is no biosimilar presence of adalimumab in this region. Moreover, the U.S. is dominating the market in North America because Humira (Adalimumab) is one of the bestselling drugs in the market. Japan is leading the growth in the Asia-Pacific region and biologics segment is dominating in this country due to first biosimilar approved in 2020 before that on biologics are used. The biologics segment in Germany is dominating the European market owing to increasing demand of cost effective treatment.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Presence of Product Pipeline and Introduction to Biosimilars are Boosting the Market Growth of Adalimumab

Adalimumab market also provides you with detailed market analysis for every country growth in Adalimumab industry with Adalimumab drugs sales, impact of advancement in the Adalimumab technology and changes in regulatory scenarios with their support for the Adalimumab market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Adalimumab Market Share Analysis

Adalimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Adalimumab market.

The major companies which are dealing in the adalimumab are AbbVie Inc., Amgen (Europe) GmbH (A Subsidiary of Amgen Inc.), CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila, Hetero Biopharma Ltd., Fresenius Kabi Deutschland GmbH (A Subsidiary of Fresenius Kabi AG), Sandoz International GmbH (A Subsidiairy of Sandoz (A Division of Novartis AG)), Pfizer Inc., Boehringer Ingelheim International GmbH, Reliance Life Sciences (A Subsidiary of Reliance Industries Limited) among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the adalimumab market.

For instance,

  • In July 2020, Kiadis Pharma had licenced its product pipeline K-NK004 to Sanofi. This product is indicated for treatment of multiple myeloma. This agreement helped the company to earn USD 20.67 million upfront which allowed it to boost up its drug development procedure.
  • In September 2016, Amgen received FDA approval for the AMJEVITA, indicated for treatment of all inflammatory conditions as Humira approved for. This product approval allowed the company to become of the best leader in biotechnology market. With this approval the companies has laid a milestone in the adalimumab market and attain a lucrative growth.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the Adalimumab market which also provides the benefit for organization to improve their offering for adalimumab.

Customization Available: Global Adalimumab Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 GLOBAL ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 GLOBAL ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 GLOBAL RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 GLOBAL ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 GLOBAL CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 GLOBAL CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 GLOBAL ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 GLOBAL PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 GLOBAL JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 GLOBAL HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 GLOBAL NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 GLOBAL ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 GLOBAL BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 GLOBAL BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 GLOBAL ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 GLOBAL 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 GLOBAL 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 GLOBAL 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 GLOBAL 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 GLOBAL ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 GLOBAL BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 GLOBAL GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 GLOBAL GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 GLOBAL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 GLOBAL PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 GLOBAL ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 GLOBAL ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 GLOBAL CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 GLOBAL ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 GLOBAL HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 GLOBAL SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 GLOBAL HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 GLOBAL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 GLOBAL HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 GLOBAL RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 GLOBAL ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 GLOBAL DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 GLOBAL OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 GLOBAL ADALIMUMAB MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 48 NORTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 49 NORTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 50 NORTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 NORTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 52 NORTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 53 NORTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 NORTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 55 NORTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 56 NORTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 57 NORTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 58 NORTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 59 U.S. ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 60 U.S. ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 U.S. BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 U.S. ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 63 U.S. ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 U.S. GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 65 U.S. ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 66 U.S. ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 67 U.S. ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 68 U.S. ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 69 CANADA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 70 CANADA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 CANADA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 CANADA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 73 CANADA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 CANADA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 75 CANADA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 76 CANADA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 77 CANADA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 78 CANADA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 79 MEXICO ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 80 MEXICO ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 MEXICO BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 82 MEXICO ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 83 MEXICO ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 MEXICO GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 85 MEXICO ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 86 MEXICO ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 87 MEXICO ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 88 MEXICO ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 89 EUROPE ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 90 EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 91 EUROPE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 92 EUROPE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 93 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 94 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 95 EUROPE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 96 EUROPE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 97 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 98 EUROPE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 99 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 100 GERMANYADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 101 GERMANYADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 102 GERMANYBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 103 GERMANYADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 104 GERMANYADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 105 GERMANY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 106 GERMANYADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 107 GERMANYADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 108 GERMANYADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 109 GERMANYADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 110 U.K ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 111 U.K ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 112 U.K BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 113 U.K ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 114 U.K ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 115 U.K GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 116 U.K ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 117 U.K ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 118 U.K ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 119 U.K ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 120 ITALY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 121 ITALY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 122 ITALY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 123 ITALY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 124 ITALY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 125 ITALY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 126 ITALY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 127 ITALY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 128 ITALY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 129 ITALY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 130 FRANCE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 131 FRANCE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 132 FRANCE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 133 FRANCE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 134 FRANCE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 135 FRANCE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 136 FRANCE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 137 FRANCE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 138 FRANCE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 139 FRANCE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 140 SPAIN ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 141 SPAIN ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 142 SPAIN BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 143 SPAIN ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 144 SPAIN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 145 SPAIN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 146 SPAIN ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 147 SPAIN ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 148 SPAIN ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 149 SPAIN ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 150 NETHERLANDS ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 151 NETHERLANDS ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 NETHERLANDS BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 NETHERLANDS ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 154 NETHERLANDS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 155 NETHERLANDS GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 156 NETHERLANDS ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 157 NETHERLANDS ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 158 NETHERLANDS ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 159 NETHERLANDS ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 160 RUSSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 161 RUSSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 162 RUSSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 163 RUSSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 164 RUSSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 165 RUSSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 166 RUSSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 167 RUSSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 168 RUSSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 169 RUSSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 170 SWITZERLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 171 SWITZERLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 172 SWITZERLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 173 SWITZERLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 174 SWITZERLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 175 SWITZERLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 176 SWITZERLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 177 SWITZERLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 178 SWITZERLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 179 SWITZERLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 180 BELGIUM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 181 BELGIUM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 182 BELGIUM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 183 BELGIUM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 184 BELGIUM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 185 BELGIUM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 186 BELGIUM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 187 BELGIUM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 188 BELGIUM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 189 BELGIUM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 190 TURKEY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 191 TURKEY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 192 TURKEY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 193 TURKEY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 194 TURKEY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 195 TURKEY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 196 TURKEY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 197 TURKEY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 198 TURKEY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 199 TURKEY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 200 AUSTRIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 201 AUSTRIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 202 AUSTRIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 203 AUSTRIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 204 AUSTRIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 205 AUSTRIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 206 AUSTRIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 207 AUSTRIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 208 AUSTRIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 209 AUSTRIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 210 NORWAY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 211 NORWAY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 212 NORWAY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 213 NORWAY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 214 NORWAY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 215 NORWAY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 216 NORWAY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 217 NORWAY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 218 NORWAY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 219 NORWAY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 220 HUNGARY ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 221 HUNGARY ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 222 HUNGARY BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 223 HUNGARY ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 224 HUNGARY ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 225 HUNGARY GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 226 HUNGARY ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 227 HUNGARY ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 228 HUNGARY ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 229 HUNGARY ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 230 LITHUANIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 231 LITHUANIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 232 LITHUANIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 233 LITHUANIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 234 LITHUANIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 235 LITHUANIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 236 LITHUANIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 237 LITHUANIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 238 LITHUANIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 239 LITHUANIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 240 IRELAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 241 IRELAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 242 IRELAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 243 IRELAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 244 IRELAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 245 IRELAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 246 IRELAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 247 IRELAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 248 IRELAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 249 IRELAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 250 POLAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 251 POLAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 252 POLAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 253 POLAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 254 POLAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 255 POLAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 256 POLAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 257 POLAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 258 POLAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 259 POLAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 260 REST OF EUROPE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 261 ASIA- PACIFIC ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 262 ASIA- PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 263 ASIA- PACIFIC ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 264 ASIA- PACIFIC BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 265 ASIA- PACIFIC ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 266 ASIA- PACIFIC ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 267 ASIA- PACIFIC GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 268 ASIA- PACIFIC ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 269 ASIA- PACIFIC ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 270 ASIA- PACIFIC ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 271 ASIA- PACIFIC ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 272 JAPANADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 273 JAPANADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 274 JAPANBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 275 JAPANADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 276 JAPANADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 277 JAPAN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 278 JAPANADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 279 JAPANADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 280 JAPANADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 281 JAPANADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 282 CHINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 283 CHINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 284 CHINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 285 CHINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 286 CHINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 287 CHINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 288 CHINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 289 CHINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 290 CHINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 291 CHINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 292 SOUTH KOREA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 293 SOUTH KOREA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 294 SOUTH KOREA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 295 SOUTH KOREA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 296 SOUTH KOREA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 297 SOUTH KOREA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 298 SOUTH KOREA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 299 SOUTH KOREA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 300 SOUTH KOREA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 301 SOUTH KOREA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 302 AUSTRALIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 303 AUSTRALIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 304 AUSTRALIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 305 AUSTRALIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 306 AUSTRALIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 307 AUSTRALIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 308 AUSTRALIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 309 AUSTRALIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 310 AUSTRALIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 311 AUSTRALIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 312 INDIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 313 INDIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 314 INDIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 315 INDIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 316 INDIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 317 INDIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 318 INDIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 319 INDIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 320 INDIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 321 INDIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 322 SINGAPORE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 323 SINGAPORE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 324 SINGAPORE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 325 SINGAPORE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 326 SINGAPORE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 327 SINGAPORE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 328 SINGAPORE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 329 SINGAPORE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 330 SINGAPORE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 331 SINGAPORE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 332 MALAYSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 333 MALAYSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 334 MALAYSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 335 MALAYSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 336 MALAYSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 337 MALAYSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 338 MALAYSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 339 MALAYSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 340 MALAYSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 341 MALAYSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 342 THAILAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 343 THAILAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 344 THAILAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 345 THAILAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 346 THAILAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 347 THAILAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 348 THAILAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 349 THAILAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 350 THAILAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 351 THAILAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 352 INDONESIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 353 INDONESIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 354 INDONESIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 355 INDONESIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 356 INDONESIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 357 INDONESIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 358 INDONESIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 359 INDONESIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 360 INDONESIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 361 INDONESIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 362 PHILIPPINES ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 363 PHILIPPINES ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 364 PHILIPPINES BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 365 PHILIPPINES ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 366 PHILIPPINES ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 367 PHILIPPINES GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 368 PHILIPPINES ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 369 PHILIPPINES ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 370 PHILIPPINES ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 371 PHILIPPINES ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 372 VIETNAM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 373 VIETNAM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 374 VIETNAM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 375 VIETNAM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 376 VIETNAM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 377 VIETNAM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 378 VIETNAM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 379 VIETNAM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 380 VIETNAM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 381 VIETNAM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 382 REST OF ASIA-PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 383 SOUTH AMERICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 384 SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 385 SOUTH AMERICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 386 SOUTH AMERICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 387 SOUTH AMERICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 388 SOUTH AMERICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 389 SOUTH AMERICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 390 SOUTH AMERICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 391 SOUTH AMERICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 392 SOUTH AMERICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 393 SOUTH AMERICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 394 BRAZILADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 395 BRAZILADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 396 BRAZILBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 397 BRAZILADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 398 BRAZILADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 399 BRAZIL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 400 BRAZILADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 401 BRAZILADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 402 BRAZILADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 403 BRAZILADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 404 ARGENTINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 405 ARGENTINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 406 ARGENTINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 407 ARGENTINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 408 ARGENTINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 409 ARGENTINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 410 ARGENTINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 411 ARGENTINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 412 ARGENTINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 413 ARGENTINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 414 PERU ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 415 PERU ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 416 PERU BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 417 PERU ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 418 PERU ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 419 PERU GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 420 PERU ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 421 PERU ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 422 PERU ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 423 PERU ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 424 REST OF SOUTH AMERICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 425 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 426 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 427 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 428 MIDDLE EAST & AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 429 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 430 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 431 MIDDLE EAST & AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 432 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 433 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 434 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 435 MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 436 SAUDI ARABIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 437 SAUDI ARABIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 438 SAUDI ARABIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 439 SAUDI ARABIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 440 SAUDI ARABIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 441 SAUDI ARABIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 442 SAUDI ARABIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 443 SAUDI ARABIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 444 SAUDI ARABIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 445 SAUDI ARABIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 446 SOUTH AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 447 SOUTH AFRICA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 448 SOUTH AFRICA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 449 SOUTH AFRICA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 450 SOUTH AFRICA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 451 SOUTH AFRICA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 452 SOUTH AFRICA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 453 SOUTH AFRICA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 454 SOUTH AFRICA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 455 SOUTH AFRICA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 456 UAE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 457 UAE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 458 UAE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 459 UAE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 460 UAE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 461 UAE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 462 UAE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 463 UAE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 464 UAE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 465 UAE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 466 ISRAEL ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 467 ISRAEL ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 468 ISRAEL BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 469 ISRAEL ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 470 ISRAEL ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 471 ISRAEL GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 472 ISRAEL ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 473 ISRAEL ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 474 ISRAEL ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 475 ISRAEL ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 476 KUWAIT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 477 KUWAIT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 478 KUWAITBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 479 KUWAIT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 480 KUWAIT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 481 KUWAIT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 482 KUWAIT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 483 KUWAIT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 484 KUWAIT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 485 KUWAIT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 486 EGYPT ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 487 EGYPT ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 488 EGYPT BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 489 EGYPT ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 490 EGYPT ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 491 EGYPT GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 492 EGYPT ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 493 EGYPT ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 494 EGYPT ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 495 EGYPT ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 496 REST OF MIDDLE EAST & AFRICA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions